ASK REDCHAT ANYTHING ABOUT ENANTA PHARMACEUTICALS INC.
Enanta Pharmaceuticals Inc. (NASDAQ: ENTA)
Listen to this Section
$11.40
-0.3350
(
-2.86% )
38.8K
Sign up for The Small Stocks Big Money Newsletter and receive free small-cap news and insights.
Clinical Trial Pipeline Stages
| Drug Name |
Stage |
| MAVYRET (Glecaprevir)DetailsHCV (Hepatitis C Virus) |
Approved |
| Zelicapavir /EDP-938 (N protein-inhibitor)DetailsViral infection, Respiratory syncytial virus, Respiratory virus |
Phase 2 |
| EDP-235DetailsViral infection, COVID-19 |
Phase 2 |
| EDP-514 (HBV Core inhibitor)DetailsHepatitis B |
Phase 2 |
| EDP-323DetailsRespiratory virus, Respiratory syncytial virus, Viral infection |
Phase 2a |
| EDP-305 (FXR Agonist)DetailsNon-alcoholic steatohepatitis |
Failed |
| ENP-297 (FXR inhibitor)DetailsNon-alcoholic steatohepatitis |
Failed |
Market Data
|
| Open |
$11.40 |
| Previous Close |
$11.73 |
| Volume |
38.8K |
| Market Cap |
$326.84M |
| Day Range |
$11.32 - $11.75 |
| 52 Week Range |
$6.44 - $17.15 |
| Shares Outstanding |
29.08M |
| Change % |
-2.86% |
| Net Change |
▼ -0.3350 |
| Insider Ownership |
-0.08% |
| Exchange |
NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations |
| IPO Year | 2013 |
| Country | United States |
| Underwriter | IPO Intelligence Only |
Insider Ownership Transactions
Total Amount Purchased:
-1,101,978.00
| Date |
Type |
Amount Purchased |
Purchaser |
| 2024-08-09 |
Sale |
-1467.00 |
Rottinghaus Scott T. |
| 2024-07-15 |
Sale |
-4299.00 |
Rottinghaus Scott T. |
| 2024-06-17 |
Sale |
-7266.00 |
Kieffer Tara Lynn |
| 2024-05-01 |
Sale |
-150000.00 |
Kowalsky Matthew Paul |
| 2024-03-08 |
Sale |
-15700.00 |
Peterson Kristine |
| 2024-03-08 |
Sale |
-15700.00 |
Russell Lesley |
| 2024-03-08 |
Sale |
-15700.00 |
Hata Yujiro S |
| 2024-03-08 |
Sale |
-15700.00 |
Vance Terry |
| 2024-03-08 |
Sale |
-15700.00 |
CARTER BRUCE L A |
| 2024-03-08 |
Sale |
-15700.00 |
FOLETTA MARK G |